Stocks in play: MYND Life Sciences Inc

Today announced that it has entered into Collaborative Research Agreement (the "Agreement") with the University of British Columbia ("UBC") focusing on Novel Therapies for Neurological Diseases. MYND is creating safe and effective precision medicines based on proprietary technologies, targeting intractable diseases affecting the Central Nervous System, aiming to improve the standard of care for patients. This research seeks to test new compounds, including Psilocybins which may modify neurological diseases. MYND Life Sciences Inc shares C.MYND are trading up 0.01 cent at $0.21.

Read:

• Biotech Sector Answering Calls for New Breast Cancer Treatment Developments in 2022

• Alternative Domestic Supplies of Critical Minerals Needed to Facilitate Energy Transition

• Flexitarians Driving Food Manufacturers to Double-Down on Plant-Based Proteins

• Drug Developers Gaining Positive Results in Fight Against Blood Cancers

• Across the Entire Food Sector, Producers Want in on the Plant-Based Protein Business